Also trades as: CHM.AX (ASX) · $vol 0M
CHMMF Earnings
Chimeric Therapeutics Limited
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
$0.10
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Last Earnings
2026-08-31
EPS
A$-0.29 (US$-0.20)
▼ Miss +0.0%
Revenue
A$5M ($3M)
▲ Beat +0.0%
Estimate vs Actual
Earnings Surprise History
2/11
EPS Beats
0/11
Revenue Beats
18%
EPS Beat Rate
0%
Rev Beat Rate
Wall Street Forward Estimates
Quarterly
Annual
Estimate Revisions
Recent Revisions
| Date | Period | Fiscal Date | EPS Old | EPS New | Change | Rev Old | Rev New |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | annual | 2027-06-30 | A$— | A$— | — | A$484,528,808 | A$481,795,590 |
| 2026-09-30 | annual | 2027-06-30 | A$— | A$— | — | A$486,776,429 | A$484,528,808 |
| 2026-09-29 | annual | 2027-06-30 | A$— | A$— | — | A$487,192,655 | A$486,776,429 |
| 2026-09-28 | annual | 2027-06-30 | A$— | A$— | — | A$486,332,454 | A$487,192,655 |
| 2026-09-25 | annual | 2027-06-30 | A$— | A$— | — | A$493,706,593 | A$486,332,454 |
| 2026-09-23 | annual | 2027-06-30 | A$— | A$— | — | A$493,713,530 | A$493,706,593 |
| 2026-09-22 | annual | 2027-06-30 | A$— | A$— | — | A$493,082,254 | A$493,713,530 |
| 2026-09-21 | annual | 2027-06-30 | A$— | A$— | — | A$494,400,304 | A$493,082,254 |
| 2026-09-17 | annual | 2027-06-30 | A$— | A$— | — | A$495,094,014 | A$494,400,304 |
| 2026-09-16 | annual | 2027-06-30 | A$— | A$— | — | A$497,251,452 | A$495,094,014 |
| 2026-09-15 | annual | 2027-06-30 | A$— | A$— | — | A$496,113,768 | A$497,251,452 |
| 2026-09-14 | annual | 2027-06-30 | A$— | A$— | — | A$500,525,764 | A$496,113,768 |
| 2026-09-11 | annual | 2027-06-30 | A$— | A$— | — | A$500,615,947 | A$500,525,764 |
| 2026-09-09 | annual | 2027-06-30 | A$— | A$— | — | A$500,775,500 | A$500,615,947 |
| 2026-09-08 | annual | 2027-06-30 | A$— | A$— | — | A$499,610,067 | A$500,775,500 |
Earnings Call Transcripts
No transcripts available.